Understanding ICER's Second Annual Launch Price and Access Report

In this episode, we welcome back Sarah Emond, President and CEO of the Institute for Clinical and Economic Review (ICER), to discuss an exciting new development in the industry: the release of ICER’s second annual Launch Price and Access Report. We dig into the report’s findings and explore why median net launch prices have climbed over the past several years, what the data show about delays and cost sharing for patients trying to get newly approved drugs, and what manufacturers, payers, and employers could do differently. Sarah makes the case for a voluntary de-escalation, with prices set in line with value and met by streamlined access. We also explore the role of purchasers, her call for a federally funded consortium of independent assessment groups, and her concerns about MFN.

• Sarah Emond, ICER

• Institute for Clinical and Economic Review (ICER) 

• Episode 26: An Interview with Sarah Emond, MPP, President and CEO, ICER

• Episode 30: The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference

• 2026 Launch Price and Access Report

• ICER Fair Access Criteria: Cornerstones of “Fair” Drug Coverage

• Medicare Part D Out-of-Pocket Cap (CMS)

• Medicaid Drug Rebate Program

• ICER Scientific Advice

• Medicare Drug Price Negotiation Program

• Peterson Health Technology Institute

• Most Favored Nation Drug Pricing

Questions or comments? Email comments@prescriptionforbetteraccess.com. Find us on X, LinkedIn, YouTube, and Threads.